Aldeyra’s Resubmitted NDA for Reproxalap Sparks 28% Stock Surge Ahead of FDA Decision
By ATTN Desk · Editorial oversight: Sean Han
Introduction
ALDEYRA THERAPEUTICS (NASDAQ: ALDX) is a clinical‐stage biotechnology company headquartered in Lexington, Massachusetts. Founded in 2004, the firm focuses on the discovery and development of treatments for immune-mediated diseases by targeting reactive aldehyde species (RASP). Its lead programs address ocular conditions such as dry eye disease and allergic conjunctivitis, as well as systemic inflammatory disorders.
Corporate Structure and Operations
Aldeyra Therapeutics operates with a team of 11–50 employees. The company maintains its research and development efforts in Lexington, Massachusetts, and is publicly traded on the NASDAQ under the ticker ALDX. According to a Schedule 13G/A filing on November 14, 2025, Perceptive Advisors LLC and Joseph Edelman jointly hold 5,222,311 shares—approximately 8.7% of the outstanding common stock—under shared voting and dispositive power.
Biotechnology by Louis Reed
Developments and News
On July 17, 2025, Aldeyra announced that the U.S. Food and Drug Administration accepted for review its resubmitted New Drug Application (NDA) for reproxalap, a topical therapy for signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date is December 16, 2025. This marks the third submission after two complete response letters in November 2023 and April 2025, both of which cited efficacy concerns but noted no safety or manufacturing issues.
In conjunction with the reproxalap program, Phase 2 proof‐of‐concept trials are underway for ADX-629 in psoriasis, asthma, and COVID-19, while clinical development continues for ADX-2191 in ophthalmic indications such as proliferative vitreoretinopathy.
A company-hosted panel discussion took place on February 26, 2025, at Nutter’s networking reception, where President and CEO Todd Brady spoke on the strategic treatment of intellectual property as a business asset.
Trading Data as of 2025-12-16
| Ticker | Exchange | Price | Change (%) | Volume | 52-Week Range | Market Cap | Cash (mrq) | Debt/Equity (mrq) | EPS (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| ALDX | NASDAQ | $5.13 | +28.45 | 4,002,521 | $1.14–$7.20 | $240.0 M | $75.3 M | 31.6% | –$0.73 |
Financial and Strategic Analysis
As of its most recent disclosure, Aldeyra held $75.3 million in cash and reported total debt representing 31.6% of equity (mrq). The company incurred a net loss of $43.19 million over the trailing twelve months, equating to a diluted EPS of –$0.73. Levered free cash flow stood at $15.58 million, while return on assets and equity were –28.94% and –64.31%, respectively.
The acceptance of the reproxalap NDA places Aldeyra at a significant juncture, as FDA approval could result in the introduction of a topical therapy for dry eye disease, a market estimated to exceed $4 billion globally. Institutional support from Perceptive Advisors and other investors indicates potential confidence in the pipeline’s prospects.
Market Position and Industry Context
Aldeyra operates within the immunology and ophthalmology sectors, which continue to present unmet needs in chronic inflammatory and autoimmune conditions. Its RASP-modulating approach seeks to address multiple inflammatory pathways rather than focusing on single cytokines or receptors. Key competitors include established ophthalmic drug manufacturers and emerging biotech firms that are developing novel immunomodulators. Aldeyra’s mid-stage and late‐stage clinical programs may provide differentiation contingent on the approval of reproxalap and the progress of additional candidates through proof-of-concept studies.
tl;dr
On December 16, 2025—the PDUFA date—the FDA is expected to determine the status of Aldeyra’s resubmitted reproxalap NDA for dry eye disease. Shares increased by 28.45% to $5.13 on the day, reflecting investor activity. Institutional holders control approximately 8.7% of common stock. Significant upcoming events include the FDA decision and updates from Phase 2 trials of ADX-629 and ongoing studies of ADX-2191.